Q3 2022 EPS Estimates for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Lowered by Analyst

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAGet Rating) – Equities researchers at SVB Leerink decreased their Q3 2022 earnings per share estimates for shares of Enanta Pharmaceuticals in a research note issued to investors on Tuesday, May 10th. SVB Leerink analyst R. Ruiz now forecasts that the biotechnology company will post earnings per share of ($1.32) for the quarter, down from their prior estimate of ($1.09). SVB Leerink currently has a “Market Perform” rating and a $68.00 price objective on the stock. SVB Leerink also issued estimates for Enanta Pharmaceuticals’ Q4 2022 earnings at ($1.04) EPS, FY2022 earnings at ($5.45) EPS, FY2023 earnings at ($7.20) EPS, FY2024 earnings at $13.30 EPS and FY2025 earnings at $20.75 EPS.

ENTA has been the topic of several other reports. StockNews.com assumed coverage on shares of Enanta Pharmaceuticals in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. Roth Capital cut their price target on shares of Enanta Pharmaceuticals from $101.00 to $70.00 in a research note on Wednesday. JMP Securities restated a “buy” rating and set a $116.00 target price on shares of Enanta Pharmaceuticals in a report on Wednesday, March 30th. Finally, Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 18th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Enanta Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $87.88.

Shares of ENTA opened at $51.50 on Thursday. The firm’s 50-day moving average is $68.02 and its two-hundred day moving average is $71.52. Enanta Pharmaceuticals has a twelve month low of $40.37 and a twelve month high of $102.00. The firm has a market capitalization of $1.06 billion, a P/E ratio of -10.34 and a beta of 0.64.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last announced its earnings results on Monday, May 9th. The biotechnology company reported ($1.63) EPS for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 108.39% and a negative return on equity of 24.62%. During the same quarter in the previous year, the firm earned ($1.09) earnings per share.

In other Enanta Pharmaceuticals news, Director Bruce L. A. Carter sold 6,000 shares of the stock in a transaction on Monday, March 21st. The shares were sold at an average price of $67.83, for a total value of $406,980.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Nathalie Adda sold 24,339 shares of the stock in a transaction on Tuesday, March 1st. The shares were sold at an average price of $70.26, for a total transaction of $1,710,058.14. The disclosure for this sale can be found here. Insiders have sold 113,683 shares of company stock worth $8,084,777 in the last 90 days. 12.42% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in ENTA. Signaturefd LLC increased its position in Enanta Pharmaceuticals by 86.7% in the 1st quarter. Signaturefd LLC now owns 392 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 182 shares in the last quarter. Robeco Institutional Asset Management B.V. bought a new position in Enanta Pharmaceuticals in the fourth quarter valued at approximately $64,000. C M Bidwell & Associates Ltd. bought a new position in Enanta Pharmaceuticals in the fourth quarter valued at approximately $85,000. Royal Bank of Canada raised its holdings in shares of Enanta Pharmaceuticals by 1,367.7% in the second quarter. Royal Bank of Canada now owns 1,409 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 1,313 shares during the last quarter. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at approximately $114,000. Institutional investors and hedge funds own 98.87% of the company’s stock.

About Enanta Pharmaceuticals (Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Further Reading

Earnings History and Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.